AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02017600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
Study NCT02017600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 70 mg/m2 on day1
Study NCT02017600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: fluorouracil 700 mg/m2 daily, day1 to day4
Study NCT00075439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT00075439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01840995 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasonographic measurement of optic nerve sheath diameter
Description: A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
Study NCT03372889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient educaiton materials - Print based
Description: Print (paper) based materials
Study NCT03372889 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient educaiton materials - Media based
Description: Media (electronic) based materials
Study NCT03584373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Oral Tablet [Toradol]
Description: Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
Study NCT03584373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
Study NCT03584373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone Acetaminophen
Description: Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
Study NCT01487577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
Study NCT03956355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof
Description: Tapinarof cream, 1%, applied once daily
Study NCT03956355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream applied once daily
Study NCT03709732 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: observational study
Study NCT00673270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: 50 µg of fludrocortisone per os
Study NCT03885934 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 15-valent PCV containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
Study NCT02714543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloevera juice
Description: aloevera juice to drink twice daily for 3 months.
Study NCT02714543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: intralesional injection of hydrocortisone 100mg once a week for 6 weeks
Study NCT02714543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: injection hyaluronic acid 1500IU once a week for 6 weeks
Study NCT03885934 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
Study NCT02943551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Feedback Reports
Description: During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~* The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~* The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores.
Study NCT02943551 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parent Survey
Description: Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
Study NCT03366844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: checkpoint inhibitor
Study NCT03366844 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT Boost
Description: The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
Study NCT04296136 — intervention group
Intervention type: OTHER
Intervention: Advance Care Planning Discussion
Description: Goals of care discussion with patient, documentation with electronic health record note and advance care planning billing. This will also include: pharmacy review of medications, case management review, and coding specialist review.
Study NCT02612714 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Description: All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
Study NCT02463591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beriplex
Description: Beriplex 50 IU/Kg i.v. , single dose.
Study NCT02463591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beriplex
Description: Beriplex 50 IU/Kg i.v. , single dose.
Study NCT00673270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 50 mg of intravenous hydrocortisone
Study NCT04133753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator-Based Intervention
Description: Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
Study NCT02308280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib following nonmyeloablative allogeneic transplant
Description: Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
Study NCT00673270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Fludrocortisone
Description: Tablet of placebo of Fludrocortisone
Study NCT00673270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Fludrocortisone
Description: Tablet of placebo of Fludrocortisone
Study NCT00673270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Hydrocortisone
Description: 2 ml of isotonic saline solution
Study NCT00673270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Hydrocortisone
Description: 2 ml of isotonic saline solution
Study NCT03828370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-SMART Intervention Group
Description: The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
Study NCT03828370 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual and Customary Information Group
Description: Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
Study NCT00976118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib (AB1010)
Description: oral masitinib 3 or 6 mg/kg/day
Study NCT00976118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo to masitinib
Study NCT02596750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedle Roller
Description: 200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
Study NCT02596750 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham microneedle Roller
Description: Flat roller without microneedles
Study NCT04127812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Savor the Flavor
Description: A series of five interactive classroom lessons focused on mindfulness in eating.
Study NCT01142128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium (esomeprazole magnesium)
Description: one 40 mg capsule per day for one month
Study NCT01142128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Nexium
Description: one capsule per day for one month
Study NCT01142128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viokase 16 (pancrelipase) + Nexium
Description: Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
Study NCT01142128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viokase 16 + placebo to Nexium
Description: Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
Study NCT00761748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Convatec Uro 2-piece
Description: Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look.
Study NCT00761748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura Uro 2-piece
Description: SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
Study NCT03745430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg (days 1 and 15, q4w) until disease progression
Study NCT03821701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entresto
Description: Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
Study NCT03821701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI/ARB
Description: Choose one of ACEI/ARB according to the clinical condition among the whole study.
Study NCT02709226 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD ( provided no DLT) with a maximum of 21 evaluable patients enrolled.
Study NCT02593032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-filled trays
Description: Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
Study NCT04028115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
Study NCT00585559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos for acetaminophen and N-acetylcysteine
Description: Placebos for acetaminophen and N-acetylcysteine
Study NCT00585559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP 1 gm every 6 hours and N-acetylcysteine placebo
Description: Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
Study NCT00611130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vigabatrin
Description: Tablets twice a day for 9 weeks
Study NCT00611130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets twice daily for 9 weeks
Study NCT02227212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U300 (new formulation of insulin glargine) HOE901
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Study NCT01938222 — intervention group
Intervention type: PROCEDURE
Intervention: Short Stitch
Description: MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
Study NCT00585559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC IV infusion at 0.5 gm hourly and APAP placebo
Description: N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
Study NCT00585559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Description: Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
Study NCT00585559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly
Description: Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
Study NCT01927718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg by mouth daily for 28 days in a 28 day cycle.
Study NCT01927718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
Study NCT01927718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
Study NCT02714543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antioxidant
Description: Capsules SM Fibro (antioxidants) once daily for 3 months.
Study NCT02714543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aloevera gel
Description: aloevera gel one scoop to be applied 3-4 times daily for 3 months
Study NCT01716208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab + Fresh Frozen Plasma
Study NCT03027505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food (RUTF)
Description: MUAC used as the primary admission and exit criteria for children with MUAC \<125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~* MUAC \<115 mm: 175 kcal /kg/day~* 115 \<MUAC \<120mm: 125kcal/kg/day~* 120 \<MUAC \<125mm: 75kcal/kg/day
Study NCT01220141 — intervention group
Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
Study NCT04288362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Participants in this arm will undergo the new care model for management of diabetes mellitus polyclinics.
Study NCT04288362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants in this arm will continue to undergo the existing care model for management of diabetes mellitus in the polyclinics.
Study NCT01558674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145
Study NCT01558674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Study NCT04560231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: 200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
Study NCT01685762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
Study NCT01558674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torsemide
Study NCT03797248 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Chinese herbal medicine
Description: All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
Study NCT01746550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-12-001 Stent
Description: MD-12-001 is a self-expanding nitinol stent
Study NCT02544737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
Study NCT01013532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100mg bid
Study NCT01013532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: Probucol 250mg bid
Study NCT01013532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol 250mg bid
Study NCT01013532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100mg qd
Study NCT01013532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of cilostazol
Description: same shape and size of active cilostazol
Study NCT01013532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of aspirin
Description: same size and shape of active aspirin 100mg
Study NCT00441935 — intervention group
Intervention type: DEVICE
Intervention: Interstim Neuromodulation
Description: Two stage procedure to implant an interstim device for neuromodulation.
Study NCT02425176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A (BoNT-A) 50U
Description: Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline